Uppsala, Sweden, 8 September 2015
Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Dr Ulf Bremberg as Chief Scientific Officer.
"We are delighted to have Ulf join Beactica at an important time for the company.” said Dr Per Källblad, CEO of Beactica. "As our internal pipeline is advancing, the appointment of Ulf underscores our increasing commitment to drug discovery. The talented research team at Beactica has successfully addressed several important targets and we can leverage our expertise and intellectual property further under Ulf’s scientific leadership.
Dr Bremberg brings significant experience from the pharmaceutical industry to Beactica, with a background in medicinal chemistry and extensive experience of industrial pharmaceutical research, especially in early discovery, patent strategies and oncology. Ulf most recently headed up the Lead Identification Facility at the Drug Discovery & Development Platform of SciLifeLab, a national pharmaceutical research infrastructure formed by a collaboration between Karolinska Institute, KTH Royal Institute of Technology, Stockholm University and Uppsala University. Earlier positions include Chief Scientific Officer of OncoTargeting AB as well as positions as Chemistry Team Leader and Medicinal Chemist at Biovitrum and Pharmacia. Ulf did his post-doc at the Scripps Research Institute and holds a Ph.D. in Organic Chemistry from KTH Royal Institute of Technology.
Professor Helena Danielson previously held the position of CSO and will remain active in the Company’s Board of Directors.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 560880.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes, Beactica offers expertise and services in the area of SPR biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR biosensor-based small molecule drug discovery.
Sign up for the Beactica newsletter to receive our latest news and updates